Tina Weinzierl
YOU?
Author Swipe
View article: The physiological interactome of TCR-like antibody therapeutics in human tissues
The physiological interactome of TCR-like antibody therapeutics in human tissues Open
Selective binding of TCR-like antibodies that target a single tumour-specific peptide antigen presented by human leukocyte antigens (HLA) is the absolute prerequisite for their therapeutic suitability and patient safety. To date, selectivi…
View article: Supplementary Figure 1 from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models
Supplementary Figure 1 from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models Open
PDF file - 62K, Internalization of GA101 (black squares), rituximab (open diamonds), and ofatumumab (open triangles) upon binding to (A) SU-DHL4 cells and (B, C) whole blood derived from two CLL patients. Samples were incubated for 0.5, 2,…
View article: Figure S5 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Figure S5 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Predicted versus observed values plots
View article: Supplementary Figure Legend from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models
Supplementary Figure Legend from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models Open
PDF file - 43K
View article: Data from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models
Data from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models Open
We report the first preclinical in vitro and in vivo comparison of GA101 (obinutuzumab), a novel glycoengineered type II CD20 monoclonal antibody, with rituximab and ofatumumab, the two currently approved type I CD20 antibodi…
View article: Supplementary Video Legend from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models
Supplementary Video Legend from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models Open
PDF file - 39K
View article: Supplementary Methods from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models
Supplementary Methods from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models Open
PDF file - 100K
View article: Section S1 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Section S1 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Supplementary section S1 describes the compound properties of cibisatamab as well as details on data generation, model development and modeling strategy applied
View article: Supplementary Figure 1 from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models
Supplementary Figure 1 from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models Open
PDF file - 62K, Internalization of GA101 (black squares), rituximab (open diamonds), and ofatumumab (open triangles) upon binding to (A) SU-DHL4 cells and (B, C) whole blood derived from two CLL patients. Samples were incubated for 0.5, 2,…
View article: Table S1 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Table S1 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Parameter description and units
View article: Supplementary Methods from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models
Supplementary Methods from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models Open
PDF file - 100K
View article: Figure S2 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Figure S2 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Experimental data triplicate values with model fit
View article: Figure S1 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Figure S1 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Detailed model schematic
View article: Supplementary Video 1 from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models
Supplementary Video 1 from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models Open
WMV file - 14044K, Time-lapse imaging of direct cell death induction in Z138 lymphoma cells treated with either rituximab, ofatumumab, or GA101. Images were taken over 5.5 h of treatment. Annexin V FLUOS (detects phosphatidylserine exposur…
View article: Data from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models
Data from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models Open
We report the first preclinical in vitro and in vivo comparison of GA101 (obinutuzumab), a novel glycoengineered type II CD20 monoclonal antibody, with rituximab and ofatumumab, the two currently approved type I CD20 antibodi…
View article: Data from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Data from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Targeted T-cell redirection is a promising field in cancer immunotherapy. T-cell bispecific antibodies (TCB) are novel antibody constructs capable of binding simultaneously to T cells and tumor cells, allowing cross-linking and the formati…
View article: Supplementary Figure 2 from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models
Supplementary Figure 2 from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models Open
PDF file - 307K, Whole-blood B-cell depletion mediated by GA101 (black squares), rituximab (open diamonds), and ofatumumab (open triangles) in lepirudin-treated (A, B) and heat-inactivated (HI) (C) whole-blood samples. GA101 mediated super…
View article: Supplementary Figure Legend from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models
Supplementary Figure Legend from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models Open
PDF file - 43K
View article: Figure S4 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Figure S4 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Prediction distribution plots of MKN45 cell line
View article: Supplementary Video 1 from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models
Supplementary Video 1 from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models Open
WMV file - 14044K, Time-lapse imaging of direct cell death induction in Z138 lymphoma cells treated with either rituximab, ofatumumab, or GA101. Images were taken over 5.5 h of treatment. Annexin V FLUOS (detects phosphatidylserine exposur…
View article: Supplementary Figure 2 from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models
Supplementary Figure 2 from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models Open
PDF file - 307K, Whole-blood B-cell depletion mediated by GA101 (black squares), rituximab (open diamonds), and ofatumumab (open triangles) in lepirudin-treated (A, B) and heat-inactivated (HI) (C) whole-blood samples. GA101 mediated super…
View article: Figure S2 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Figure S2 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Experimental data triplicate values with model fit
View article: Data from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Data from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Targeted T-cell redirection is a promising field in cancer immunotherapy. T-cell bispecific antibodies (TCB) are novel antibody constructs capable of binding simultaneously to T cells and tumor cells, allowing cross-linking and the formati…
View article: Table S1 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Table S1 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Parameter description and units
View article: Figure S3 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Figure S3 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Dose-response profiles over time of various cytokines and T cell markers from assays with MNK45 and CX1 cell lines
View article: Table S2 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Table S2 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Estimated parameter values
View article: Figure S5 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Figure S5 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Predicted versus observed values plots
View article: Figure S4 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Figure S4 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Prediction distribution plots of MKN45 cell line
View article: Section S1 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling
Section S1 from Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling Open
Supplementary section S1 describes the compound properties of cibisatamab as well as details on data generation, model development and modeling strategy applied
View article: Supplementary Video Legend from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models
Supplementary Video Legend from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models Open
PDF file - 39K